| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Suven Life Sciences Limited (NSE: SUVEN)
SUVEN Technical Analysis
4
| As on 25th Apr 2024 SUVEN SHARE Price closed @ 113.60 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 70.09 & Buy for SHORT-TERM with Stoploss of 93.22 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SUVENSHARE Price
| Open | 117.95 | Change | Price | % |
| High | 118.05 | 1 Day | 1.15 | 1.02 |
| Low | 112.10 | 1 Week | 1.75 | 1.56 |
| Close | 113.60 | 1 Month | 1.75 | 1.56 |
| Volume | 558699 | 1 Year | 58.00 | 104.32 |
| 52 Week High 101.55 | 52 Week Low 45.50 | ||||
NSE INDIA Most Active Stocks
| IDEA | 13.90 | 6.11% |
| YESBANK | 25.95 | 1.96% |
| KOTAKBANK | 1642.45 | -10.87% |
| SOUTHBANK | 30.40 | 4.47% |
| SAIL | 164.95 | 0.18% |
| PNB | 135.90 | 2.18% |
| TATASTEEL | 167.70 | 1.30% |
| AXISBANK | 1127.00 | 6.00% |
| IRFC | 150.25 | 0.84% |
| IOB | 66.90 | 5.77% |
NSE INDIA Top Gainers Stocks
| ROML | 75.65 | 19.98% |
| POWERINDIA | 9329.50 | 13.60% |
| GPTINFRA | 211.80 | 12.51% |
| NEOGEN | 1557.75 | 12.25% |
| PNC | 65.00 | 11.02% |
| PNC | 65.00 | 11.02% |
| PNC | 65.00 | 11.02% |
| PNC | 65.00 | 11.02% |
| MOIL | 430.70 | 10.88% |
| GODFRYPHLP | 3449.70 | 10.17% |
NSE INDIA Top Losers Stocks
| SUVEN Daily Charts |
SUVEN Intraday Charts |
Whats New @ Bazaartrend |
SUVEN Free Analysis |
|
|
SUVEN Important Levels Intraday
| RESISTANCE | 125.07 |
| RESISTANCE | 121.39 |
| RESISTANCE | 119.12 |
| RESISTANCE | 116.84 |
| SUPPORT | 110.36 |
| SUPPORT | 108.08 |
| SUPPORT | 105.81 |
| SUPPORT | 102.13 |
SUVEN Target April 2024
| 4th UP Target | 134.88 |
| 3rd UP Target | 127.49 |
| 2nd UP Target | 122.93 |
| 1st UP Target | 118.36 |
| 1st DOWN Target | 105.34 |
| 2nd DOWN Target | 100.77 |
| 3rd DOWN Target | 96.21 |
| 4th DOWN Target | 88.82 |
SUVEN Weekly Target
| 4th UP Target | 134.88 |
| 3rd UP Target | 127.49 |
| 2nd UP Target | 122.93 |
| 1st UP Target | 118.36 |
| 1st DOWN Target | 105.34 |
| 2nd DOWN Target | 100.77 |
| 3rd DOWN Target | 96.21 |
| 4th DOWN Target | 88.82 |
SUVEN Target2024
| 4th UP Target | 165.06 |
| 3rd UP Target | 138.02 |
| 2nd UP Target | 121.31 |
| 1st UP Target | 104.59 |
| 1st DOWN Target | 56.91 |
| 2nd DOWN Target | 40.19 |
| 3rd DOWN Target | 23.48 |
| 4th DOWN Target | -3.56 |
Suven Life Sciences Limited ( NSE INDIA Symbol : SUVEN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SUVEN Synopsis Technicals View
| 50 Day EMA |
Close is Above EMA 50 (Short Term) |
Bullish | |
| 100 Day EMA | Close is Below EMA 100 (Mid Term) | Bearish | |
| 200 Day EMA | Close is Below EMA 200 (Long Term) | Bearish | |
| MACD (12 26 9) | MACD Line is Grater Then SIGNAL Line | Bullish | |
| RSI (14) | RSI is Below 30 | Over Sold | |
| MFI (14) | MFI is Below 20 | Over Sold | |
| CCI (20) | CCI is Below -100 | Over Sold | |
| WILLIAM %R (14) | William %R is Below -80 | Over Sold | |
| ADX (14) | ADX is Above 20 & +DI is Below -DI | Down Trend | |
| PSAR | Stoploss For Short Sell | 151.94 | |
| 10 Day Avg Volume | Traded -70.15 % Less then 10 Day Average Volume | ||
SUVEN Other Details
| Segment | EQ | |
| Market Capital | 12823661568.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
SUVEN Address
 |
||
SUVEN Latest News
SUVEN Business Profile
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. It engages in drug discovery and development of new chemical entities (NCE) in central nervous system therapies. The company's product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. It is also develops SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited. Address: # 8-2-334, SDE Serene Chambers, Hyderabad, India, 500034
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service